A Brief Note On The Dormant Form Of Tuberculosis ( Tb )
832 WordsNov 15, 20144 Pages
• A huge caution associated with the use of adalimumab is its ability to reactivate, or make one more susceptible to infection. This is because it inhibits TNFα which plays a role in the fighting of infections. Reactivating the dormant form of tuberculosis (TB) is one of the most important infectious adverse reactions in those taking adalimumab. Consequently, patients are assessed for tuberculosis before being offered adalimumab. Other infections include septicaemia and hepatitis B. As a general rule of thumb, evaluation for infection before, during and 4 months post treatment should occur. Treatment should not be started until the infection is controlled and it is advised that adalimumab be avoided in patients on drugs that alter immune function (e.g. immunosuppressants).
• Respiratory tract infections such as sinitis, lower and upper tract infections are most commonly reported. Other common side effects are nausea, headaches and rash.
• Live vaccines are also advised to be avoided in patients taking adalimumab, despite the lack of supporting evidence that concomitant use causes significant harm or affects the efficacy of either treatment.
• Asides from infections, adalimumab has been shown to cause reactions at the injection site including rashes (sometimes in the form of urticaria – itchy rash), eczema, reddening skin sometimes accompanied by pain and swelling. As an antibody, adalimumab is structurally able to trigger an immune response where parts of it can be